Pharma Pulse: FDA Grants Priority Review to Rusfertide and Expands Approval for Novo Nordisk’s Sogroya Podcast Por  arte de portada

Pharma Pulse: FDA Grants Priority Review to Rusfertide and Expands Approval for Novo Nordisk’s Sogroya

Pharma Pulse: FDA Grants Priority Review to Rusfertide and Expands Approval for Novo Nordisk’s Sogroya

Escúchala gratis

Ver detalles del espectáculo
In today’s Pharma Pulse, the FDA grants priority review to a therapy for polycythemia vera, while Novo Nordisk receives expanded pediatric approval for its once-weekly growth hormone.
Todavía no hay opiniones